சர்வதேச மெட்டாஸ்டேடிக் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சர்வதேச மெட்டாஸ்டேடிக். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சர்வதேச மெட்டாஸ்டேடிக் Today - Breaking & Trending Today

Data from Merck's Oncology Portfolio Highlight Significant Advances in Cancer Care at ASCO21


Data from Merck’s Oncology Portfolio Highlight Significant Advances in Cancer Care at ASCO21
Saturday, May 22, 2021 12:20PM IST (6:50AM GMT)
 
New analyses from pivotal BAVENCIO
® study reinforce unique clinical benefits across different subgroups in the treatment of advanced urothelial carcinoma
New data from VISION study of TEPMETKO
® show association between liquid biopsy-identified biomarker and clinical response in
METex14 skipping NSCLC, supporting liquid biopsy as a means for monitoring treatment response
TEPMETKO
Oral presentations from independent studies reinforce the position of ERBITUX
® in 1L RAS wt mCRC and as backbone of treatment in SCCHN
 
Not intended for UK-, US- or Canada-based media ....

United States , Julissa Viana , Eli Lilly , International Metastatic , American Society Of Clinical Oncology , National Cancer Institute , Merck Press , European Commission , Drug Administration , Merck Kga , Global Head Of Development For The Healthcare , Merck Kgaa , Data Consortium , American Society , Clinical Oncology , Annual Meeting , Danny Bar Zohar , Global Head , Data Highlights , Solid Tumor , Product Characteristics , Merck Press Releases , Media Contact , Merck Oncology , Cancer Care , Clinical Benefits ,

'Obesity Paradox' in Kidney Cancer Continues in Checkpoint Inhibitor Era


email article
Elevated BMI was tied to improved survival in metastatic renal cell carcinoma (RCC) patients treated with immune checkpoint inhibitors, a retrospective study found.
In the analysis of more than 700 metastatic RCC patients who received PD-1/L1 immunotherapies, those with a BMI of 25 or greater had significantly longer overall survival (OS), with 1-year rates of 79% versus 66% for those with a BMI below that cutoff (HR 0.75, 95% CI 0.57-0.97,
P=0.03), Toni Choueiri, MD, of Dana-Farber Cancer Institute in Boston, and colleagues reported.
These findings are consistent with the obesity paradox that was previously seen during the VEGF-targeted therapy era, the group wrote in ....

United States , Dana Farber Cancer Institute , Toni Choueiri , Ian Ingram , International Metastatic , Database Consortium , Medpage Today , Deputy Managing Editor , Clear Cell Carcinoma Of Kidney , Malignant Tumor Of Kidney , Neoplasm Of Kidney , ஒன்றுபட்டது மாநிலங்களில் , டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம் , ஈயந் இஂக்ரம் , சர்வதேச மெட்டாஸ்டேடிக் , தரவுத்தளம் கூட்டமைப்பு , துணை நிர்வகித்தல் ஆசிரியர் , தெளிவானது செல் புற்றுநோய் ஆஃப் கிட்நீ , வீரியம் மிக்கது கட்டி ஆஃப் கிட்நீ , உடல் பருமன் ,